Pharmaceutical Pipeline

Our understanding of ACC’s potential allows us to leverage it for the treatment of hypoparathyroidism–a rare endocrine disorder characterized by dysfunction or decreased function of the parathyroid glands, which causes underproduction of parathyroid hormone (PTH).

What Does Hypoparathyroidism Have to Do with Calcium?

PTH regulates the absorption and use of calcium in our body. Hypoparathyroidism can lead to low blood calcium levels (hypocalcemia), causing bone, muscle and neurological disorders. People who have this rare disease must take high doses of calcium supplement every day to maintain a normal calcium level in their blood.

What Causes Hypoparathyroidism?

Hypoparathyroidism can be inherited (primary hypoparathyroidism) or caused by trauma to a parathyroid gland during thyroid surgery (secondary hypoparathyroidism).

Amorphical Invests Millions in Clinical Research of ACC

In a clinical study involving patients with hypoparathyroidism, all the subjects managed to maintain normal blood calcium levels while taking ACC tablets at doses that were 50% of their previous doses of other types of calcium supplement. Based on this study, Amorphical received the FDA’s approval to continue to a Phase 2 and 3 study worldwide. The study, which is due to begin later this year in the US and Europe, will be a multicenter study under the FDA Orphan Drug program.